Home » Newsletters » BioWorld Science

BioWorld Science

April 1, 2022

View Archived Issues

BLU-945 for treatment-resistant EGFR T790M mutation-driven lung cancer

Medshine Discovery divulges thyroid hormone receptor beta agonists

Galderma discovers JAK-1 inhibitors

New NFE2-related factor 2 activators described by Sanofi

CNRS and collaborators patent acetylcholinesterase reactivators

RemeGen discloses new anti-c-Met antibody-drug conjugates

Telomere to telomere, the human genome is done

Novel humanized HIS-BRGS mouse model to evaluate immune-related kidney toxicities

New orthotopic xenograft breast cancer murine models developed

Humanized mouse model to asses acute toxicity of immune drug treatments

Sosei Heptares presents novel GLP-1 receptor antagonist HTL-0033097

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 17, 2026.
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’
BioWorld
The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...